DLST-dependence dictates metabolic heterogeneity in TCA-cycle usage among triple-negative breast cancer

[1]  E. Mjolsness,et al.  Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing , 2020, Nature Cell Biology.

[2]  Yi Yao,et al.  Risk factors for distant metastasis of patients with primary triple-negative breast cancer , 2019, Bioscience reports.

[3]  Jeffrey T. Chang,et al.  Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state , 2019, Science Translational Medicine.

[4]  Austin E. Gillen,et al.  Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia , 2018, Nature Medicine.

[5]  Sung-Bae Kim,et al.  How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies , 2018, ESMO Open.

[6]  S. Fesik,et al.  MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. , 2017, Cell metabolism.

[7]  F. Filipp,et al.  Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities , 2017, Cancer & metabolism.

[8]  L. Emens.  Breast Cancer Immunotherapy: Facts and Hopes , 2017, Clinical Cancer Research.

[9]  B. Tromberg,et al.  CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation , 2017, Proceedings of the National Academy of Sciences.

[10]  J. Balko,et al.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease , 2016, Nature Reviews Clinical Oncology.

[11]  D. Neuberg,et al.  The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis , 2016, Leukemia.

[12]  B. Faubert,et al.  Myc induces expression of glutamine synthetase through promoter demethylation , 2015 .

[13]  L. Pusztai,et al.  Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential , 2014, Breast Cancer Research.

[14]  P. Bingham,et al.  A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process , 2014, Cancer & metabolism.

[15]  Jennifer B Dennison,et al.  Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer , 2014, Molecular Cancer Therapeutics.

[16]  J. Gray,et al.  Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. , 2013, Cancer cell.

[17]  R. Elledge,et al.  Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up , 2012, Breast Cancer Research and Treatment.

[18]  G. Sauter,et al.  Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer , 2012, Breast Cancer Research and Treatment.

[19]  Z. Nahleh,et al.  Glut-1 Expression Correlates with Basal-like Breast Cancer. , 2011, Translational oncology.

[20]  Abhishek K. Jha,et al.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011, Nature.

[21]  J. Chi,et al.  Glutamine Synthetase Is a Genetic Determinant of Cell Type–Specific Glutamine Independence in Breast Epithelia , 2011, PLoS genetics.

[22]  Chris Sander,et al.  18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. , 2011, Cancer research.

[23]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[24]  L. Carey,et al.  Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. , 2009, Clinical breast cancer.

[25]  A. Imbalzano,et al.  Increasingly transformed MCF-10A cells have a progressively tumor-like phenotype in three-dimensional basement membrane culture , 2009, Cancer Cell International.

[26]  R. Deberardinis,et al.  Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.

[27]  Anne E Carpenter,et al.  A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen , 2006, Cell.

[28]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[29]  D. Wallace,et al.  Selective killing of cells with oxidative defects in galactose medium: A screening test for affected patient fibroblasts , 1992, Journal of Inherited Metabolic Disease.

[30]  D. Wallace,et al.  Nonviability of cells with oxidative defects in galactose medium: a screening test for affected patient fibroblasts. , 1992, Biochemical medicine and metabolic biology.

[31]  L. Reitzer,et al.  Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. , 1979, The Journal of biological chemistry.

[32]  Xiang Zhang,et al.  In-Gel Stable-Isotope Labeling (ISIL): a strategy for mass spectrometry-based relative quantification. , 2006, Journal of proteome research.